AZD2461: Novel PARP Inhibitor for Advanced Breast Cancer Research

Executive Summary: AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 value of 5 nM, specifically targeting PARP-1 to disrupt DNA repair in cancer cells (APExBIO). It induces G2 phase cell cycle arrest and reduces S phase populations in human breast cancer cell lines under standard in vitro conditions (Schwartz 2022). AZD2461 exhibits reduced affinity for P-glycoprotein (Pgp), offering advantages over traditional PARP inhibitors by potentially overcoming multidrug resistance mechanisms. In vivo administration in BRCA1-mutated mouse tumor models prolongs median relapse-free survival without notable toxicity. The compound's robust solubility profile in DMSO and ethanol and recommended use at 5–50 μM for 48–72 hours in cell culture make it suitable for translational breast cancer research workflows.

Biological Rationale

Poly (ADP-ribose) polymerase enzymes, particularly PARP-1, play a fundamental role in DNA repair, chromatin remodeling, and programmed cell death (apoptosis) (Schwartz 2022). Defective DNA repair pathways, such as those seen in BRCA1-mutated breast cancers, increase cellular reliance on PARP-mediated repair. Inhibiting PARP leads to accumulation of DNA damage, synthetic lethality, and selective cancer cell death. PARP inhibitors are thus critical tools in breast cancer research, precision oncology, and studies of DNA repair pathway modulation. AZD2461, developed and distributed by APExBIO, offers enhanced selectivity for PARP-1 and lower affinity for drug-efflux pumps, addressing historical limitations of earlier PARP inhibitors (APExBIO).

Mechanism of Action of AZD2461

AZD2461 inhibits PARP-1 enzymatic activity at nanomolar concentrations, blocking the synthesis of poly (ADP-ribose) chains required for single-strand DNA break repair (Reference). In MCF-7 and SKBR-3 breast cancer cells, AZD2461 reduces viable cell numbers in a concentration- and time-dependent manner, with maximal effects observed after 48–72 hours at 5–50 μM. Mechanistically, AZD2461 induces cell cycle arrest in G2 phase and reduces S phase populations, as demonstrated by flow cytometry and cell cycle analysis. In vivo, AZD2461 achieves sustained PARP inhibition in tumor tissue for several hours post-administration, with PAR levels returning to baseline after 24 hours. The compound’s low affinity for Pgp reduces the risk of efflux-mediated resistance, distinguishing it from olaparib and other first-generation PARP inhibitors (Related Article).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 with an IC50 of 5 nM in biochemical assays (APExBIO).
• Exposure of MCF-7 and SKBR-3 cells to 5–50 μM AZD2461 for 48–72 hours results in significant reduction of viable cells and G2 phase cell cycle arrest (Schwartz 2022).
• In vivo, AZD2461 administration in BRCA1-mutated KB1P mouse tumor models inhibits tumor PARP activity for hours and prolongs median relapse-free survival without notable toxicity (Schwartz 2022).
• AZD2461 shows lower affinity for P-glycoprotein compared to olaparib, reducing susceptibility to Pgp-mediated drug resistance (Reference).
• The compound is insoluble in water but soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonic assistance), facilitating diverse in vitro applications (APExBIO).

The present article extends the mechanistic discussion in "AZD2461: Novel PARP Inhibitor for Breast Cancer Research" by providing new quantitative evidence and workflow integration strategies. It also updates the translational perspective offered in "AZD2461: Advancing PARP Signaling Insights for Precision ..." by highlighting recent in vivo efficacy benchmarks.

Applications, Limits & Misconceptions

AZD2461 is optimized for the study of DNA repair pathway modulation, cancer cell cycle dynamics, and drug resistance mechanisms in breast cancer models. Its use is particularly relevant in translational research involving BRCA1/2-mutated contexts and preclinical evaluation of relapse-free survival extension strategies. However, the compound has boundaries and potential misconceptions:

Common Pitfalls or Misconceptions

• AZD2461 is not effective in cell lines or tumors with restored homologous recombination proficiency (e.g., BRCA-wildtype contexts), where synthetic lethality is not achieved.
• It does not directly induce apoptosis but primarily causes cell cycle arrest; secondary cell death may be context-dependent (Schwartz 2022).
• The compound is not water-soluble; improper dissolution protocols can compromise experimental results.
• Long-term storage of AZD2461 solutions at ambient temperatures leads to degradation; only short-term (days) storage at -20°C is recommended (APExBIO).
• While AZD2461 shows lower Pgp affinity, resistance may still develop via alternative efflux pathways or compensatory DNA repair activation.

Workflow Integration & Parameters

For in vitro applications, AZD2461 should be dissolved in DMSO or ethanol to the desired concentration (5–50 μM). Typical incubation times are 48–72 hours at 37°C and 5% CO₂. Use of validated breast cancer cell lines (MCF-7, SKBR-3) enhances data comparability. PARP activity can be assessed via western blot or ELISA for poly (ADP-ribose) levels. In vivo, AZD2461 can be dosed in BRCA1-mutated mouse models, with PAR levels monitored at multiple time points post-administration. For additional protocol guidance, consult the product documentation at APExBIO AZD2461 or AZD2461: A Paradigm Shift in PARP Inhibition for Translat..., which this article clarifies and systematizes by adding updated solubility and cell cycle data.

Conclusion & Outlook

AZD2461, as distributed by APExBIO, is a robust tool for advanced breast cancer research, enabling precise modulation of the DNA repair pathway and investigation of Pgp-independent drug resistance. Its nanomolar potency, selectivity for PARP-1, and improved pharmacological profile over first-generation PARP inhibitors support its integration into translational workflows. Ongoing research will clarify its full utility in diverse genetic contexts and potential for clinical translation (Schwartz 2022).